Near-infrared resonant photoacoustic gas measurement using simultaneous dual-frequency excitation

The simultaneous dual-frequency operation of a resonant photoacoustic gas sensor based on the differential mode excitation photoacoustic (DME-PA) technique is presented. The DME-PA method uses the excitation of two different modes in a resonant photoacoustic cell and the gas concentration is derived from the amplitude ratio of these acoustic modes. With the simultaneous dual-frequency excitation, the amplitude ratio needed by the DME-PA technique is obtained instantaneously, in contrast to the sequential modulation scheme where additional time delays are introduced by changing the modulation frequency. For a given excitation power reaching the photoacoustic cell, and a total acquisition time longer than 7s, the simultaneous modulation scheme provides an improved measurement uncertainty compared to the sequential scheme. The proposed sensor allows measuring water vapour with a ±150 ppmV uncertainty using current-modulated near-infrared LEDs and a 15s total acquisition tim

Considerations for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the United States

Background: An increasing number of HIV cure trials involve combining multiple potentially curative interventions. Until now, considerations for designing and implementing complex combination HIV cure trials have not been thoroughly considered. Methods: We used a purposive method to select key informants for our study. Informants included biomedical HIV cure researchers, regulators, policy makers, bioethicists, and community members. We used in-depth interviews to generate ethical and practical considerations to guide the design and implementation of combination HIV cure research. We analyzed the qualitative data using conventional content analysis focused on inductive reasoning. Results: We interviewed 11 biomedical researchers, 4 community members, 2 regulators, 1 policy researcher, and 1 bioethicist. Informants generated considerations for designing and implementing combination interventions towards an HIV cure, focused on ethical aspects, as well as considerations to guide trial design, benefit/risk determinations, regulatory requirements, prioritization and sequencing and timing of interventions, among others. Informants also provided considerations related to combining specific HIV cure research modalities, such as broadly neutralizing antibodies (bNAbs), cell and gene modification products, latency-reversing agents and immune-based interventions. Finally, informants provided suggestions to ensure meaningful therapeutic improvements over standard antiretroviral therapy, overcome challenges of designing combination approaches, and engage communities around combination HIV cure research. Conclusion: The increasing number of combination HIV cure trials brings with them a host of ethical and practical challenges. We hope our paper will inform meaningful stakeholder dialogue around the use of combinatorial HIV cure research approaches. To protect the public trust in HIV cure research, considerations should be periodically revisited and updated with key stakeholder input as the science continues to advance

Very long optical path-length from a compact multi-pass cell

The multiple-pass optical cell is an important tool for laser absorption spectroscopy and its many applications. For most practical applications, such as trace-gas detection, a compact and robust design is essential. Here we report an investigation into a multi-pass cell design based on a pair of cylindrical mirrors, with a particular focus on achieving very long optical paths. We demonstrate a path-length of 50.31 m in a cell with 40 mm diameter mirrors spaced 88.9 mm apart - a 3-fold increase over the previously reported longest path-length obtained with this type of cell configuration. We characterize the mechanical stability of the cell and describe the practical conditions necessary to achieve very long path-lengths

An intercomparison of CH3O2 measurements by Fluorescence Assay by Gas Expansion and Cavity Ring–Down Spectroscopy within HIRAC (Highly Instrumented Reactor for Atmospheric Chemistry)

Simultaneous measurements of CH3O2 radical concentrations have been performed using two different methods in the Leeds HIRAC (Highly Instrumented Reactor for Atmospheric Chemistry) chamber at 295 K and in 80 mbar of a mixture of 3 : 1 He : O2 and 100 mbar or 1000 mbar of synthetic air. The first detection method consisted of the indirect detection of CH3O2 using the conversion of CH3O2 into CH3O by excess NO with subsequent detection of CH3O by fluorescence assay by gas expansion (FAGE). The FAGE instrument was calibrated for CH3O2 in two ways. In the first method, a known concentration of CH3O2 was generated using the 185 nm photolysis of water vapour in synthetic air at atmospheric pressure followed by the conversion of the generated OH radicals to CH3O2 by reaction with CH4 / O2. This calibration can be used for experiments performed in HIRAC at 1000 mbar in air. In the second method, calibration was achieved by generating a near steady-state of CH3O2 and then switching off the photolysis lamps within HIRAC and monitoring the subsequent decay of CH3O2 which was controlled via its self-reaction, and analysing the decay using second order kinetics. This calibration could be used for experiments performed at all pressures. In the second detection method, CH3O2 has been measured directly using Cavity Ring-Down Spectroscopy (CRDS) using the absorption at 7487.98 cm-1 in the A <– X (ν12) band with the optical path along the ~1.4 m chamber diameter. Analysis of the second-order kinetic decays of CH3O2 by self-reaction monitored by CRDS has been used for the determination of the CH3O2 absorption cross section at 7487.98 cm-1, both at 100 mbar of air and at 80 mbar of a 3 : 1 He : O2 mixture, from which σCH3O2 = (1.49 ± 0.19) × 10–20 cm2 molecule-1 was determined for both pressures. The absorption spectrum of CH3O2 between 7486 and 7491 cm-1 did not change shape when the total pressure was increased to 1000 mbar, from which we determined that σCH3O2 is independent of pressure over the pressure range 100–1000 mbar in air. CH3O2 was generated in HIRAC using either the photolysis of Cl2 with UV black lamps in the presence of CH4 and O2 or the photolysis of acetone at 254 nm in the presence of O2. At 1000 mbar of synthetic air the correlation plot of [CH3O2]FAGE against [CH3O2]CRDS gave a gradient of 1.10 ± 0.02. At 100 mbar of synthetic air the gradient of the FAGE – CRDS correlation plot had a gradient of 1.06 ± 0.01 and at 80 mbar of 3 : 1 He : O2 mixture the correlation plot gradient was 0.91 ± 0.02. These results provide a validation of the FAGE method to determine concentrations of CH3O2

Engineering of lipid-coated PLGA nanoparticles with a tunable payload of diagnostically active nanocrystals for medical imaging

Polylactic-co-glycolic acid (PLGA) based nanoparticles are biocompatible and biodegradable and therefore have been extensively investigated as therapeutic carriers. Here, we engineered diagnostically active PLGA nanoparticles that incorporate high payloads of nanocrystals into their core for tunable bioimaging features. We accomplished this through esterification reactions of PLGA to generate polymers modified with nanocrystals. The PLGA nanoparticles formed from modified PLGA polymers that were functionalized with either gold nanocrystals or quantum dots exhibited favorable features for computed tomography and optical imaging, respectively.National Heart, Lung, and Blood Institute (Programs of Excellence in Nanotechnology (PEN) Award, Contract #HHSN268201000045C))National Institutes of Health (U.S.) (R01 EB009638)National Institutes of Health (U.S.) (R01 CA155432)National Institutes of Health (U.S.) (K99 EB012165)Netherlands Organization for Scientific Research ((NWO) ECHO.06.B.047

The spatial distribution of HO2in an atmospheric pressure plasma jet investigated by cavity ring-down spectroscopy

Cold atmospheric pressure plasma jets make important contributions to a range of fields, such as materials processing and plasma medicine. In order to optimise the effect of those plasma sources, a detailed understanding of the chemical reaction networks is pivotal. However, the small diameter of plasma jets makes diagnostics challenging. A promising approach to obtain absolute number densities is the utilisation of cavity-enhanced absorption spectroscopy methods, by which line-of-sight averaged densities are determined. Here, we present first measurements on how the spatial distribution of HO2 in the effluent of a cold atmospheric pressure plasma jet can be obtained by cavity ring-down spectroscopy in an efficient way. Instead of recording fully wavelength resolved spectra, we will demonstrate that it is sufficient to measure the absorption coefficient at two wavelengths, corresponding to the laser being on and off the molecular resonance. By sampling the effluent from the 1.6 mm diameter nozzle in the radial direction at various axial positions, we determined that the distances over which the HO2 density was distributed were (3.9 ± 0.5) mm and (6.7 ± 0.1) mm at a distance of 2 mm and 10 mm below the nozzle of the plasma jet, respectively. We performed an Abel inversion in order to obtain the spatial distribution of HO2 that is presented along the symmetry axis of the effluent. Based on that localised density, which was (4.8 ± 0.6) ⋅ 1014 cm-3 at the maximum, we will discuss the importance of the plasma zone for the production of HO2

Ethical and practical considerations for HIV cure-related research at the end-of-life: a qualitative interview and focus group study in the United States

Background: One of the next frontiers in HIV research is focused on finding a cure. A new priority includes people with HIV (PWH) with non-AIDS terminal illnesses who are willing to donate their bodies at the end-of-life (EOL) to advance the search towards an HIV cure. We endeavored to understand perceptions of this research and to identify ethical and practical considerations relevant to implementing it. Methods: We conducted 20 in-depth interviews and 3 virtual focus groups among four types of key stakeholders in the United States (PWH, biomedical HIV cure researchers, HIV clinicians, and bioethicists) to obtain triangulated viewpoints because little was known about the ethics of this topic. Each group was queried as to ethical considerations, safeguards, and protections for conducting HIV cure-related research at the EOL to ensure this research remains acceptable. Results: All four key stakeholder groups generally supported HIV cure-related research conducted at the EOL because of the history of altruism within the PWH community and the potential for substantial scientific knowledge to be gained. Our informants expressed that: (1) Strong stakeholder and community involvement are integral to the ethical and effective implementation, as well as the social acceptability of this research; (2) PWH approaching the EOL should not inherently be considered a vulnerable class and their autonomy must be respected when choosing to participate in HIV cure-related research at the EOL; (3) Greater diversity among study participants, as well as multi-disciplinary research teams, is necessitated by HIV cure-related research at the EOL; (4) The sensitive nature of this research warrants robust oversight to ensure a favorable risk/benefit balance and to minimize the possibility of therapeutic misconception or undue influence; and (5) Research protocols should remain flexible to accommodate participants’ comfort and needs at the EOL. Conclusion: Because of the ethical issues presented by HIV cure-related research at the EOL, robust ethical safeguards are of utmost importance. The proposed ethical and practical considerations presented herein is a first step in determining the best way to maximize this research’s impact and social value. More much inquiry will need to be directed towards understanding context-specific and cultural considerations for implementing EOL HIV cure research in diverse settings

Ethical and practical considerations for interventional HIV cure-related research at the end-of-life: A qualitative study with key stakeholders in the United States

Background A unique window of opportunity currently exists to generate ethical and practical considerations presented by interventional HIV cure-related research at the end-of-life (EOL). Because participants would enroll in these studies for almost completely altruistic reasons, they are owed the highest ethical standards, safeguards, and protections. This qualitative empirical ethics study sought to identify ethical and practical considerations for interventional HIV cure-related research at the EOL. Methods and findings We conducted 20 in-depth interviews and three virtual focus groups (N = 36) with four key stakeholder groups in the United States: 1) bioethicists, 2) people with HIV, 3) HIV care providers, and 4) HIV cure researchers. This study produced six key themes to guide the ethical implementation of interventional HIV cure-related research at the EOL: 1) all stakeholder groups supported this research conditioned upon a clearly delineated respect for participant contribution and autonomy, participant understanding and comprehension of the risks associated with the specific intervention(s) to be tested, and broad community support for testing of the proposed intervention(s); 2) to ensure acceptable benefit-risk profiles, researchers should focus on limiting the risks of unintended effects and minimizing undue pain and suffering at the EOL; 3) only well-vetted interventions that are supported by solid pre-clinical data should be tested in the EOL translational research model; 4) the informed consent process must be robust and include process consent; 5) research protocols should be flexible and adopt a patient/participant centered approach to minimize burdens and ensure their overall comfort and safety; and 6) a participant’s next-of-kin/loved ones should be a major focus of EOL research but only if the participant consents to such involvement

Validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving tuberculosis treatment.

Drug susceptibility testing (DST) is often needed in patients clinically failing tuberculosis (TB) therapy. Most studies of phenotypic direct drug susceptibility tests, such as microscopic observation drug susceptibility (MODS) tests, have been performed in patients not receiving TB treatment. The effect of ongoing TB treatment on the performance of MODS direct DST has not been previously explored, but patients failing such therapy constitute an important target group. The aim of this study was to determine the performance of MODS direct rifampicin and isoniazid DST in patients clinically failing first-line TB treatment, and to compare MODS direct DST with indirect proportion method DST. Sputa from 264 TB patients were cultured in parallel in Lowenstein-Jensen (LJ) and MODS assays; strains were tested for rifampicin and isoniazid susceptibility by the proportion method at the national reference laboratory. Ninety-three samples were culture-positive by LJ and MODS (concordance of 96%; kappa 0.92). With conventional MODS plate DST reading (performed on the same day as the sample is classified as culture-positive), the isoniazid DST concordance was 96.8% (kappa 0.89), and the concordance for rifampicin susceptibility testing was 92.6% (kappa 0.80). Reading of MODS DST plates 1 week after cultures had been determined to be culture-positive improved overall performance marginally-the isoniazid DST concordance was 95.7% (kappa 0.85); and the rifampicin DST concordance was 96.8% (kappa 0.91). Sensitivity for detection of multidrug-resistant TB was 95.8%. MODS testing provided reliable rifampicin and isoniazid DST results for samples obtained from patients receiving TB therapy. A modified DST reading schedule for such samples, with a final reading 1 week after a MODS culture turns positive, marginally improves the concordance with reference DST